U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C20H22N4O2
Molecular Weight 350.4143
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of C-1311

SMILES

CCN(CC)CCNC1=C2C3=C(C=C1)N=CN3C4=C(C=C(O)C=C4)C2=O

InChI

InChIKey=CUNDRHORZHFPLY-UHFFFAOYSA-N
InChI=1S/C20H22N4O2/c1-3-23(4-2)10-9-21-15-6-7-16-19-18(15)20(26)14-11-13(25)5-8-17(14)24(19)12-22-16/h5-8,11-12,21,25H,3-4,9-10H2,1-2H3

HIDE SMILES / InChI

Molecular Formula C20H22N4O2
Molecular Weight 350.4143
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

C-1311 is an imidazoacridinone analog. It is a next-generation investigational anticancer drug. It is an antitumor inhibitor of topoisomerase II and FMS-like tyrosine kinase 3 receptor. It was evaluated in phase I and II clinical trials for the treatment of various types of tumors. Mild treatment-related adverse events were thrombocytopenia, anemia, nausea, vomiting and diarrhea. Serious adverse event is neutropenia.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P06786
Gene ID: 855636.0
Gene Symbol: TOP2
Target Organism: Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)
8.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18828924 DOI: 10.1200/jco.2008.26.15_suppl.1055
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Doses

Doses

DosePopulationAdverse events​
640 mg/m2 1 times / week multiple, intravenous (unknown)
MTD
Dose: 640 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 640 mg/m2, 1 times / week
Sources:
unhealthy
n = 2
Health Status: unhealthy
Condition: advanced solid tumours
Sex: unknown
Food Status: UNKNOWN
Population Size: 2
Sources:
DLT: neutropaenia...
Dose limiting toxicities:
neutropaenia (grade 4, 2 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
neutropaenia grade 4, 2 patients
DLT
640 mg/m2 1 times / week multiple, intravenous (unknown)
MTD
Dose: 640 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 640 mg/m2, 1 times / week
Sources:
unhealthy
n = 2
Health Status: unhealthy
Condition: advanced solid tumours
Sex: unknown
Food Status: UNKNOWN
Population Size: 2
Sources:
PubMed

PubMed

TitleDatePubMed
Pharmaceutical development of a parenteral lyophilised dosage form for the novel anticancer agent C1311.
2005 Sep-Oct
Patents

Sample Use Guides

In Vivo Use Guide
Sources: DOI: 10.1200/jco.2008.26.15_suppl.1055
The initial dose was 480 mg/m2, 1 hr IV infusion on d 1, 8, and 15 of a 28 day cycle.
Route of Administration: Intravenous
In Vitro Use Guide
Acute treatments (3 h) of the a human tumour line (HeLa S3) revealed that cells exposed to C-1311 levels, which first induced persistent G2 arrest (0.5 ug/ml), subsequently died from this compartment, while doses exceeding these levels (1.0 ug/ml), paradoxically, did not cause the same extensive cell death.
Substance Class Chemical
Created
by admin
on Fri Dec 15 17:56:24 GMT 2023
Edited
by admin
on Fri Dec 15 17:56:24 GMT 2023
Record UNII
MZ4Y5H4OAB
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
C-1311
Common Name English
NSC-645809
Code English
XLS-002
Common Name English
SYMADEX
Common Name English
C 1311
Common Name English
IMIDAZOACRIDONE
Systematic Name English
Code System Code Type Description
EPA CompTox
DTXSID10160508
Created by admin on Fri Dec 15 17:56:24 GMT 2023 , Edited by admin on Fri Dec 15 17:56:24 GMT 2023
PRIMARY
ChEMBL
CHEMBL338604
Created by admin on Fri Dec 15 17:56:24 GMT 2023 , Edited by admin on Fri Dec 15 17:56:24 GMT 2023
PRIMARY
NSC
645809
Created by admin on Fri Dec 15 17:56:24 GMT 2023 , Edited by admin on Fri Dec 15 17:56:24 GMT 2023
PRIMARY
MESH
C098965
Created by admin on Fri Dec 15 17:56:24 GMT 2023 , Edited by admin on Fri Dec 15 17:56:24 GMT 2023
PRIMARY
FDA UNII
MZ4Y5H4OAB
Created by admin on Fri Dec 15 17:56:24 GMT 2023 , Edited by admin on Fri Dec 15 17:56:24 GMT 2023
PRIMARY
PUBCHEM
132127
Created by admin on Fri Dec 15 17:56:24 GMT 2023 , Edited by admin on Fri Dec 15 17:56:24 GMT 2023
PRIMARY
CAS
138154-39-9
Created by admin on Fri Dec 15 17:56:24 GMT 2023 , Edited by admin on Fri Dec 15 17:56:24 GMT 2023
PRIMARY
Related Record Type Details
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> INHIBITOR
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> INHIBITOR
time- and concentration-dependent inhibitor
Related Record Type Details
ACTIVE MOIETY